PROM1 and melanoma: The current study therefore aimed to target CD133+ NRAS-mutant melanoma stem cells and the tumors derived from them with capivasertib, a pan-AKT inhibitor which has shown cytotoxicity against other human cancers, in order to increase the efficacy of trametinib by simultaneously inhibiting both AKT and the MAPK pathway in resistant cells.